GE would seem like a logical partner....but any cash rich company or a PE shop will do and there's plenty of cash sitting on big pharma balance sheets. Maybe Soros Capital???
So, the partner could dish out cash to fund operations in return for 50% of potential revenues for the currently un-partnered portions of programs and any future programs or something like that? That would beat buying GTC since they would have to purchase the company ($100+ million), fund operations and also face the risk of failure. In this case, they have a call option on the success of GTC with a total loss equal to cash to fund the operations.
One would think GTC's shares would fly on a deal like this since it gets the cash it needs without dilution and as long as they don't have to give away too much revenue its a win-win situation for everyone involved. Management can then focus on finding more ways to apply its IP (vs. how it can raise cash).
Dew, what are your thoughts about a financing partner?
TIA,
10nis
Market Data 
Markets 
AI
